PZPinar Engin Zerk

Pinar Engin Zerk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pinar Engin Zerk has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Primary cervical multifocal medulloblastoma: a unique case report and review of the literature

    by Mehmet Ali Kahraman, Pınar Engin Zerk, Başak Atalay, Mehmet Sabri Gürbüz

  • RB1 Loss as a Diagnostic Clue in a High‐Grade Glioma With Pleomorphic and Pseudopapillary Features (HPAP): The First Reported Case With Spinal Metastasis and a Review of the Literature

    by Furkan Aknar, Tuce Soylemez‐Akkurt, Pinar Engin Zerk, Basak Atalay, Mehmet Sabri Gürbüz, Numan Karaarslan

    High‐grade glioma with pleomorphic and pseudopapillary features (HPAP) is a recently described entity defined by a distinct DNA methylation signature, recurrent monosomy 13, and mutations in TP53, RB1, and NF1. Most cases are supratentorial with a relatively favorable prognosis. We report a 45‐year‐old woman who presented with a right cerebellar mass exhibiting striking histopathological heterogeneity comprising low‐grade and high‐grade components. The high‐grade component demonstrated a p53 null immunophenotype and complete loss of RB1 expression, contrasting with wild‐type staining in the low‐grade areas. Molecular analysis confirmed pathogenic variants in TP53 (p.Pro27LeufsTer17), NF1, and NF2, with losses of chromosomes 13 and 17. Despite gross total resection and adjuvant chemoradiotherapy, the patient developed spinal intradural metastasis 26 months postoperatively. The metastatic lesion mirrored the high‐grade primary component immunohistochemically and harbored a newly acquired TERT promoter mutation. DNA methylation profiling of the spinal metastasis classified the tumor as HPAP. This case represents the first documented spinal metastasis and the first p53 null phenotype in HPAP, suggesting a potential role for combined RB1 and p53 immunohistochemistry in the diagnostic workup and highlighting the capacity for neuraxis dissemination in this emerging entity.

  • Alternatively activated monocyte-derived myeloid cells promote extracellular pathogen persistence in pulmonary fungal granulomas

    by Yufan Zheng, Makheni Jean Pierre, Eduard Ansaldo, Hannah E. Dobson, Olena Kamenyeva, Chinaemerem U. Onyishi, Sarah Douglas, Christopher Febres Aldana, Pinar Engin Zerk, Irini Sereti, et al.

    Inhaled fungal pathogens often generate granuloma-contained latent infections that can reactivate to cause invasive disease. However, why protective pathways fail to achieve sterilizing immunity in this setting is unclear. Here, we identify type 2 inflammation as a major arm of immunosuppression during latent, granulomatous fungal infection. Using reporter mice, we found that TH2 cells were the dominant source of type 2 cytokines and deletion of IL-4/IL-13, Stat6, or TH2 cells drove fungal clearance. Type 2 signaling acted on monocyte-derived myeloid cells that formed an ARG1+ ring around the granuloma core. STAT6 was required cell intrinsically in this compartment, and its loss reduced lung burden. Contrary to an intracellular-niche model, we found that Cryptococcus was predominantly extracellular in vivo. STAT6 deficiency did not enhance macrophage intracellular killing, but instead antagonized IFNγ-dependent protection against extracellular yeast. These findings identify a spatially organized TH2-STAT6 checkpoint that limits IFNγ-mediated extracellular killing and maintains cryptococcal latency.


  • Melatonin and Methylprednisolone Combination Ameliorates Inflammation and Enhances Recovery After Sciatic Nerve Crush Injury

    by Gökçenur Yalçın, Başak Bilir Kaya, Emre Ata, Cumaali Demirtaş, Hakan Beyaztas, Gülnihal Ay, Pınar Engin Zerk, Eray Metin Guler

    This sham‐controlled animal study aimed to investigate the effects of melatonin and methylprednisolone combination on motor function, nerve conduction and histopathological and biochemical findings in rats with sciatic nerve crush injury. Forty‐eight male Sprague–Dawley rats were divided into 6 groups ( n = 8): CT: control, VEH: sciatic nerve injury, LMP: 15‐mg/kg methylprednisolone, high‐dose methylprednisolone (HMP): 30‐mg/kg methylprednisolone, MEL: 15‐mg/kg melatonin, MMP: 15‐mg/kg methylprednisolone+15‐mg/kg melatonin. The rats were evaluated with Sciatic Functional Index (SFI), nerve conduction study, interleukin‐1β ( IL‐1ß), nerve growth factor (NGF), total antioxidant status (TAS), total oxidant status (TOS) and histopathological scores. There were no significant intergroup differences in baseline tests. SFI significantly improved in all treated groups with no significant intergroup differences. Motor amplitude improved most in MMP, LMP and MEL, respectively. Nerve conduction velocity significantly improved in MMP compared to VEH. There were no significant intergroup differences regarding serum NGF, TAS and TOS. Tissue NGF levels were higher in LMP, HMP and MEL. IL‐1ß levels were significantly lower in CT and MMP. Tissue oxidative stress levels were significantly lower in treated groups compared to VEH, with no significant difference among them. MMP showed greater histopathological improvement. Melatonin combination therapy in sciatic nerve crush injury provided adequate functional improvement, superior electrophysiological and histopathological recovery compared to high‐dose methylprednisolone and exhibited better anti‐inflammatory activity through IL‐1ß.


  • Dowling-degos Disease: A Case Report

    by Selma Şengiz Erhan, Tülin Yüksel, Pınar Engin Zerk


  • Open Access

    Calretinin immunohistochemical staining in hirschprungs disease: an institutional experience

    by Ebru Zemheri, Pinar Engin Zerk, Cigdem Ulukaya Durakbasa

    OBJECTIVE: This study aims to evaluate the results obtained by calretinin staining on tissue samples for diagnosing Hirschsprung's disease (HD) in a single institution, by single expert. METHODS: A retrospective evaluation was done for calretinin immunostaining in HD patients for a period of 3 years. Calretinin staining was evaluated in nerve fibers. Calretinin immunohistochemistry was considered positive if any staining was seen in nerve fibers and/or ganglion cells in the lamina propria, muscularis mucosa or submucosa. According to staining intensity, staining was classified as strong, weak or negative. The pathological diagnosis was based on presence or absence of ganglion cells (G0/G1) and nerve hypertrophy (N0/N1). Samples were classified according to the depth (presence of submucosa or intermuscular area), the type (biopsy or resection specimen) and staining intensity of calretinin (strong, weak, or negative staining). RESULTS: A total of 96 tissue samples from 56 patients were studied. Tissues were from colon (43.8%), rectum (43.8%), stoma (6.2%), ileum (3.1%) and appendix (3.1%). The pathological diagnosis was G0N0 in 14.6%, G1N0 in 54.2%, G0N1 in 25% and G1N1 in 6.2% of cases. Our materials consisted of 92 tissue biopsies and four resection specimens. Intermuscular layer was present in 87.5% of materials and 12.5% of biopsies contained submucosa. Calretinin staining was negative (C0) in 37.5% of cases, strong positive (C1) in 47.9%, and weak positive (C2) in 14.6%. When the C0 category was taken as the reference, the status of calretinin staining as C2 (weak positive) in cases with pathological diagnosis of G1N0 was found to be 37.575 times that of cases with G0N0 (OR [95% CI]: 37.575 [2.928, 482.176], p=0.006) and the status of calretinin staining as C1 (strong positive) in cases with pathologic diagnosis of G1N0 was found to be 131.401 times that of G0N0 (OR [95% CI]: 131.401 [9.263, 1864.082), p<0.001). CONCLUSION: Calretinin staining is positive whenever ganglion cells are present independent from presence of nerve hypertrophy, the depth and the site of the biopsy or staining intensity. It is negative in all aganglionic samples. Calretinin staining is a reliable ancillary test in HD diagnosis.


  • Open Access

    Evaluation of microvessel density with CD31 and CD105 in patients with psoriasis under methotrexate and acitretin therapy

    by Ebru Zemheri, Ayşe Karadağ, Ilkin Zindancı, Pınar Zerk, Melike Ozturk

    Introduction Methotrexate and acitretin are known to be effective in the treatment of psoriasis, but the mechanisms of the effects of these drugs are not fully known. Aim To investigate the effect of methotrexate and acitretin on microvessel density (MVD) in psoriasis. Material and methods...